Showing results (1291-1300 of 1,841) with videos related to

Sort By:
Pageof 185
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
JTCVS Open|April 10, 2026
Endoscopic findings predictive of pathologic upstaging in T2N0 esophageal cancerLillian L Tsai, Sidharth Bommakanti, Ntemena Kapula, et al.
Virology Journal|November 3, 2009
Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment successGlen J Mcintyre, Yi-Hsin Yu, Anna Tran, et al.
Leukemia & Lymphoma|October 1, 2016
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromesPrashant Sharma, Shivani S Shinde, Moussab Damlaj, et al.
American Journal of Hematology|September 26, 2018
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelideAyalew Tefferi, Natasha Szuber, Rangit R Vallapureddy, et al.
Annals of Allergy|September 1, 1981
HLA-B8 in sarcoidosisS A Olenchock, E R Heise, J J Marx, et al.
JTCVS Open|January 11, 2024
Risk of developing subsequent primary lung cancer after receiving radiation for breast cancerLye-Yeng Wong, Ntemena Kapula, Hao He, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 26, 2023
Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in EnglandRachel A Elliott, Gabriel Rogers, Mark L Evans, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Pageof 185